Afatinib monotherapy did not reduce tumor growth in any of the models tested except for LX1042, a PDX derived from an EGFR-mutant adenocarcinoma that transformed to SCLC on targeted therapy (Fig. 6H). Here, EGFR is linked to adenocarcinoma.